Skip to content

Harrow HROW Non-cash interest expense

Non-cash interest expense at other companies

Bausch + Lomb logo
Bausch + LombBLCO
Bausch Health Companies logo
Bausch Health CompaniesBHC
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
PBH
Prestige Consumer HealthcarePBH

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Harrow’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harrow's non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's non-cash interest expense?
Harrow (HROW) reported non-cash interest expense of $451K in Q1 2026.
How has Harrow's non-cash interest expense changed year-over-year?
Harrow's non-cash interest expense decreased by 64.6% year-over-year, from $1.28M to $451K.
What is the long-term trend for Harrow's non-cash interest expense?
Over 4 years (2021 to 2025), Harrow's non-cash interest expense has grown at a 56.4% compound annual growth rate (CAGR), from $677K to $4.05M.